A client with myasthenia gravis receives a new prescription for pyridostigmine. Which information should the nurse to administering the medication?

A. Trouble sleeping: Sleep disturbances are not a primary concern before administering pyridostigmine, as the drug’s main adverse effects involve cholinergic symptoms. Insomnia does not influence the immediate safety or effectiveness of the medication. B. Unexplained weight loss: Although weight loss may be associated with myasthenia gravis or nutritional difficulties, it is not a critical factor to assess before giving pyridostigmine. The drug’s absorption and dosing are not directly adjusted based on weight loss. C. Difficulty with urination: Pyridostigmine can cause increased urinary frequency or exacerbate bladder issues due to cholinergic effects. However, this is not as immediate a priority as confirming oral intake, which directly affects drug absorption and onset of action. D. Recent oral intake: Pyridostigmine is best absorbed when taken with food to minimize gastrointestinal upset and optimize absorption. Ensuring the client has recently eaten, or will eat shortly after administration, helps reduce side effects such as nausea.